Contemporary Challenges to Treating Wet Age-related Macular Degeneration and Diabetic Macular Edema

A roundtable held at the American Society of Retina Specialists 2023 meeting.

Videos From Regeneron

Goals and Challenges in Treating Wet AMD and DME

Diana V. Do, MD; David S. Chin Yee, MD; Esther L. Kim, MD; Charles C. Wykoff, MD, PhD

The Role of Fluid Stability in Obtaining Disease Control

Diana V. Do, MD; David S. Chin Yee, MD; Esther L. Kim, MD; Charles C. Wykoff, MD, PhD

Treatment Durability

Diana V. Do, MD; David S. Chin Yee, MD; Esther L. Kim, MD; Charles C. Wykoff, MD, PhD

Resources

Contemporary Challenges to Treating Wet Age-related Macular Degeneration and Diabetic Macular Edema

View Resource

About Regeneron

Regeneron is a leading biotechnology company that invents, develops, and commercializes life-transforming medicines for people with serious diseases. Founded and led for nearly 35 years by physician-scientists, Regeneron's unique ability to repeatedly and consistently translate science into medicine has led to numerous FDA-approved treatments and product candidates in development, almost all of which were homegrown in Regeneron's laboratories.

Visit us online: regeneron.com

Follow Regeneron